Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.61 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.51 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.51 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.51 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.48 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.44 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11096571 | 1.00 | GSR (0.61) | GSRGNAI3GNAO1GNAI1PAOX | |
| SCHEMBL11102371 | 1.00 | GSR (0.61) | GSRGNAI3GNAO1GNAI1PAOX | |
| SCHEMBL19816538 | 1.00 | GSR (0.61) | GSRGNAI3GNAO1GNAI1PAOX | |
| SCHEMBL13456509 | 1.00 | GSR (0.61) | GSRGNAI3GNAO1GNAI1PAOX | |
| SCHEMBL7778074 | 1.00 | GSR (0.61) | GSRGNAI3GNAO1GNAI1PAOX | |
| SCHEMBL19816440 | 1.00 | GSR (0.61) | GSRGNAI3GNAO1GNAI1PAOX | |
| SCHEMBL2603680 | 0.98 | GSR (0.64) | GSRGNAI3GNAO1GNAI1PAOX | |
| SCHEMBL12277980 | 0.98 | GSR (0.64) | GSRGNAI3GNAO1GNAI1PAOX | |
| SCHEMBL2043064 | 0.98 | GSR (0.64) | GSRGNAI3GNAO1GNAI1PAOX | |
| Hydrochloric Acid SCHEMBL11548666 | 0.95 | GSR (0.61) | GSRGNAI3GNAO1GNAI1PAOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220016153-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-20 | — | — | US | disclosed |
| US-9012429-B2 | Methods and compositions for the prevention of and treatment of infections utilizing chitosan-derivative compounds | SYNEDGEN, INC. (US) | 2015-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220016153-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | ENTPD1, NME2, NME1 | GSR 2887/4885GNAI3 2512/4885GNAO1 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.